Prostate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an update
- PMID: 22792092
- PMCID: PMC3389736
- DOI: 10.1155/2012/801610
Prostate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an update
Abstract
Prostate cancer and the androgen deprivation therapy (ADT) thereof are involved in diabetes in terms of diabetes-associated carcinogenesis and ADT-related metabolic disorder, respectively. The aim of this study is to systematically review relevant literature. About 218,000 men are estimated to be newly diagnosed with prostate cancer every year in the United States. Approximately 10% of them are still found with metastasis, and in addition to them, about 30% of patients with nonmetastatic prostate cancer recently experience ADT. Population-based studies have shown that dissimilar to other malignancies, type 2 diabetes is associated with a lower incidence of prostate cancer, whereas recent large cohort studies have reported the association of diabetes with advanced high-grade prostate cancer. Although the reason for the lower prevalence of prostate cancer among diabetic men remains unknown, the lower serum testosterone and PSA levels in them can account for the increased risk of advanced disease at diagnosis. Meanwhile, insulin resistance already appears in 25-60% of the patients 3 months after the introduction of ADT, and long-term ADT leads to a higher incidence of diabetes (reported hazard ratio of 1.28-1.44). Although the possible relevance of cytokines such as Il-6 and TNF-α to ADT-related diabetes has been suggested, its mechanism is poorly understood.
Similar articles
-
Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.Pharmacotherapy. 2008 Dec;28(12):1511-22. doi: 10.1592/phco.28.12.1511. Pharmacotherapy. 2008. PMID: 19025432 Review.
-
Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer.Cancer Causes Control. 2018 Aug;29(8):785-791. doi: 10.1007/s10552-018-1050-z. Epub 2018 Jun 29. Cancer Causes Control. 2018. PMID: 29959604 Free PMC article.
-
Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.Eur Urol. 2014 Apr;65(4):816-24. doi: 10.1016/j.eururo.2013.02.023. Epub 2013 Feb 22. Eur Urol. 2014. PMID: 23453420 Free PMC article.
-
Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.Int J Cancer. 2016 Dec 15;139(12):2698-2704. doi: 10.1002/ijc.30403. Epub 2016 Sep 19. Int J Cancer. 2016. PMID: 27557616 Free PMC article.
-
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9. doi: 10.1210/jc.2007-2595. Epub 2008 Mar 18. J Clin Endocrinol Metab. 2008. PMID: 18349064 Review.
Cited by
-
Prostate cancer risk in pre-diabetic men: a matched cohort study.Clin Med Res. 2013 Dec;11(4):201-9. doi: 10.3121/cmr.2013.1160. Epub 2013 May 8. Clin Med Res. 2013. PMID: 23656798 Free PMC article.
-
Cancer Biology and Prevention in Diabetes.Cells. 2020 Jun 2;9(6):1380. doi: 10.3390/cells9061380. Cells. 2020. PMID: 32498358 Free PMC article. Review.
-
Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs.Cancer Cell Int. 2021 Sep 17;21(1):499. doi: 10.1186/s12935-021-02202-5. Cancer Cell Int. 2021. PMID: 34535145 Free PMC article. Review.
-
From obesity to diabetes and cancer: epidemiological links and role of therapies.Br J Cancer. 2016 Mar 29;114(7):716-22. doi: 10.1038/bjc.2016.37. Epub 2016 Feb 23. Br J Cancer. 2016. PMID: 26908326 Free PMC article. Review.
-
Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold.Int J Clin Oncol. 2020 Mar;25(3):472-478. doi: 10.1007/s10147-019-01527-6. Epub 2019 Aug 22. Int J Clin Oncol. 2020. PMID: 31440861
References
-
- Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ. Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer and Prostatic Diseases. 2011;14(4):326–331. - PubMed
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer Journal for Clinicians. 2010;60(5):277–300. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous